Articles tagged with Antibodies
A recent study published in PLOS ONE and American Journal of Pathology suggests that Lyme bacteria can survive a 28-day course of antibiotics for months after infection. The study found living B. burgdorferi spirochetes in ticks and multiple organs of primates treated with doxycycline, as well as persistent infections in some subjects.
A study of 142 women and 12 men found an association between maternal immune response to the Y-linked protein NLGN4Y and sexual orientation in male offspring. Higher antibody concentrations were detected in mothers of homosexual sons compared to those with heterosexual sons or no sons.
Researchers say new diagnostic methods can accurately detect Lyme disease earlier, improving patient outcomes and avoiding severe long-term health problems. The improved tests are less susceptible to false-positive or false-negative results associated with current antibody-based tests.
Researchers from Helmholtz Munich used computer analysis to study IgG antibodies and reveal new steps in the glycosylation pathway. The findings confirmed predictions made by an algorithm and were replicated using genome-wide association studies and laboratory experiments.
Researchers at the German Cancer Research Center found that natural infection with malaria induces a strong immune response, producing antibodies that protect mice from infection. The study's findings will help develop more effective and specific vaccines against the disease.
Scientists have developed Trim-Away, a novel method that directly and quickly depletes proteins from any cell type. This technique utilizes a protein called Trim21 to recognize antibodies directed against specific cellular proteins, allowing researchers to study their function in natural environment.
Scientists provide detailed picture of how human antibodies bind to malaria parasite's circumsporozoite protein, a key target for vaccine development. The study could lead to enhanced efficacy and duration of protection against malaria.
A recent study by La Jolla Institute for Allergy and Immunology reveals that dengue immunity can confer protection against Zika virus. Cytotoxic T-cells have been identified as crucial in defending against both viruses, suggesting that vaccines targeting either dengue or Zika could be effective.
A new study found that a mutation in the H3N2 strain of the virus is responsible for the low efficacy of last year's influenza vaccine. The team suggests investing in new technologies to produce egg-free vaccines, while emphasizing the importance of annual flu vaccination.
Researchers at the University of Louisville discovered a new autoimmune disease that causes kidney failure, dubbed anti-brush border antibody (ABBA) disease. The disease was identified after analyzing biopsied kidney tissue from patients with acute kidney injury, and it affects the nephrons' brush borders by coating them with antibodies.
A new study in Nicaraguan children pinpoints a narrow window of antibody levels that enhances reaction to severe dengue, shedding light on the long-standing phenomenon of antibody-dependent enhancement (ADE). The findings hold important implications for vaccine development against dengue and related flaviviruses like Zika.
Researchers found that blocking IL-17A and IL-17F significantly reduces symptoms of severe allergic asthma in mice. The study suggests a new potential treatment for people with this condition, by preventing the production of pro-inflammatory molecules triggered by T-helper cells.
Scientists have discovered that weak binding between antibodies and biological gels like mucus is more effective in trapping pathogens, making it a stronger first line of defense. This finding has the potential to revolutionize the treatment and prevention of various diseases by providing new targets for engineered antibodies.
A study published in Nature Immunology has found that a specific type of immune cell, called T follicular regulatory cells, plays a crucial role in preventing autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus after viral infections. These cells prevent the generation of self-reactive antibody responses whil...
A newly-developed dipstick test sensitively identified Zika virus and all four dengue virus subtypes with no cross-reactivity. The test detected viral proteins at lower concentrations, making it a potential tool for diagnosing emerging pathogens.
A new paper-based test developed by MIT researchers can diagnose Zika infection within 20 minutes, accurately distinguishing it from Dengue virus. The test uses antibodies specific to Zika virus's NS1 protein, avoiding false positives common with existing tests.
A new study shows an antibody that prevents dengue disease also protects mice from Zika. Administering the antibody soon after infection can protect fetuses from Zika-related birth defects.
A new study by University of Nottingham researchers found that a positive mood on the day of flu vaccination can significantly increase its protective effect. The study, which measured factors such as mood, physical activity and diet, showed that good mood was associated with higher levels of antibody after vaccination.
Researchers found that a combination of two broadly-neutralizing HIV-1 antibodies protected primates against infection with a mixed population of HIV viruses. The findings suggest that combination therapies might be essential to prevent HIV in people, highlighting the need for regimens that protect against several targets.
A new study reveals how the immune system avoids becoming cancerous by using a hair-trigger protein called Tia1. This protein controls the production of proteins needed to fix damaged DNA, allowing B cells to produce effective antibodies while preventing lasting harm.
Researchers have found a way to generate long-lasting immune cells that can respond to and stop HIV virus infection. The team demonstrated that a modified gp140 protein approach improves B-cell responses, boosting the ability of B-cells to make protective antibodies against HIV.
Researchers have created antibody-recruiting molecules targeting fungi (ARM-Fs) that can attach to fungal cell walls and recruit human antibodies to combat infections. These small molecules offer a new strategy for treating fungal diseases affecting thousands of people each year.
Researchers at Scripps Research Institute discover a way to reprogram mature skin-like cells into stem cells using antibodies, potentially reducing mutations and improving properties. This method could lead to personalized cell therapies and organ regeneration.
Rice University scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells by adding rhodium, a rare transition metal. The new technique allows labs to test the relative function of various antibody sources and antigen targets to see which will work best on tumor cells.
Researchers at Hokkaido University have developed a chimeric anti-PD-L1 antibody that induces immune responses and tumor regression in dogs with malignant cancers. The antibody targets PD-L1-positive cancers, including oral malignant melanoma and undifferentiated sarcoma.
Research published in Annals of the Rheumatic Diseases found a link between prolonged use of oral contraceptives and reduced risk of developing rheumatoid arthritis. However, breastfeeding was not associated with a significant protective effect after accounting for influential factors.
A new study by Texas Tech University Health Sciences Center El Paso researchers explores the impact of prior West Nile virus exposure on Zika infection. The team collected blood samples from 500 individuals and tested for West Nile antibodies to determine whether previous exposure could inhibit or enhance Zika infection severity.
Scientists have discovered a specific type of immune regulatory cell, T follicular regulatory cells (Tfr), in patients with Sjögren syndrome, an autoimmune disease. Blood Tfr cells are immature and unable to suppress antibody production, but their levels increase in response to flu vaccine exposure.
Researchers at Arizona State University have developed a plant-based Zika vaccine that is more potent, safer and cheaper to produce than existing alternatives. The vaccine targets the DIII domain of the Zika virus and has been shown to induce 100% protection against multiple Zika virus strains in mice.
A new portable platform enables sensitive and rapid diagnostic testing in resource-limited settings, detecting telltale markers of disease as accurately as the most sensitive tests on the market. The D4 assay can identify a disease biomarker in as few as 15 minutes.
A new study found that prior dengue or yellow fever exposure does not increase susceptibility to severe Zika virus infection in rhesus macaques. The researchers observed no significant differences in clinical factors between previously infected and uninfected monkeys after Zika virus infection.
Researchers found that treating patients with IdeS drug before transplantation significantly reduced donor-specific antibodies, allowing successful kidney transplants. The enzyme, produced by Streptococcus pyogenes, can remove organ-rejecting antibodies, making kidney transplantation possible.
Researchers found that prior vaccination in pregnant women did not significantly affect the transfer of flu antibodies to their babies, contradicting initial concerns. Weakened maternal immune responses from repeated flu shots also hindered peak antibody levels.
Researchers have developed a new method to generate specific human antibodies in the laboratory using nanoparticles. This technique can produce high-affinity antibodies within days, offering potential for rapid therapeutic antibody production and accelerated vaccine development.
A team of researchers has successfully manufactured microscopic versions of silkworm cocoons, which can store and protect sensitive molecular materials. The tiny capsules, made from silk nano-fibrils, have the potential to increase the stability and lifetime of antibodies used in pharmaceuticals for treating severe diseases.
A team led by Prof. Arne Skerra has identified an antibody that tightly binds benzopyrene, a widespread environmental toxin linked to cancer. This breakthrough could lead to the development of antibodies to separate aromatic hydrocarbons from contaminated drinking water.
Researchers at TUM have identified an antibody that tightly binds benzo[a]pyrene, a widespread environmental toxin linked to cancer. This breakthrough discovery may lead to the development of antibodies against other PAHs and improved methods to separate contaminants from drinking water.
Tulane University has received a $12 million grant to test a promising drug treatment for Lassa fever and develop a vaccine against the deadly disease. The vaccine targets a recently discovered key antibody target on the surface of the virus, which can block it from infecting host cells.
A recent study by Duke University researchers demonstrates a vaccine approach that appears to protect fetuses from congenital CMV infection. The findings, published in JCI Insight, suggest potent antibodies can prevent viral transmission and severe disease in developing fetuses.
A recent study by the University of Zurich found that exposure to sialic acid from farm animals can prevent asthma in children. This protective effect is due to an anti-inflammatory response triggered by regulatory T-cells, which dampen incorrect immune responses.
Researchers at CNIC reveal CTCF's crucial role in antibody generation and germinal center formation, shedding light on the immune response mechanisms. The study highlights the importance of CTCF for maintaining proper immune function and has implications for vaccine research.
Researchers found that maternal antibodies against HSV-1 can travel to the nervous systems of unborn babies, preventing the development and spread of infection during birth. This protection may help prevent serious brain disease related to these conditions in fetuses and newborns.
Researchers at Cornell University discovered a new way to measure tiny amounts of antibodies in foals, helping to understand how quickly they start producing their own. This will aid in optimizing vaccination schedules for young horses.
Researchers have demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma. The treatment targets a protein called sclerostin, which halts bone formation, and found to double bone volume in some mice.
Researchers at Duke University Medical Center have discovered a new antibody that can restore the effectiveness of chemotherapy rituximab in leukemia patients with natural resistance. The study found that adding the antibody to rituximab increased cancer cell death by 45% in five out of 11 patients.
Researchers develop Affimer technology to replicate antibodies, providing a more robust, smaller, and easier-to-modify alternative. This tool enables scientists to study molecular behavior and reactions with ease, leading to breakthroughs in disease research.
Researchers at Université de Genève have developed a new test to detect anti-phospholipid antibody syndrome (APS), an autoimmune disease affecting around 0.5% of the population. The test targets the specific antibody that binds to cells, producing pro-inflammatory and pro-thrombotic factors, offering improved accuracy and standardization.
Researchers elucidate mechanisms behind synaptic vesicle motion, finding that type, size of synapse and vesicle composition impact motility. Tracking vesicles reveals active transport to specific destinations, providing clues for neuronal diseases.
Researchers found that Zika viral load and dengue antibodies were not associated with severe symptoms or fetal harm, contradicting previous theories. The study's findings suggest a lack of correlation between the amount of virus in the blood and severity of symptoms in pregnant women.
Researchers developed a 3-D crystal structure of the disease's molecular interactions with a neural receptor, providing a clear view of how it attacks and destroys proteins. The model could accelerate research and lead to new therapies for myasthenia gravis, which affects an estimated 36,000 to 60,000 Americans annually.
Scientists at Johns Hopkins created a nanoparticle that carries two different antibodies to simultaneously switch off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. The 'immunoswitch' particles dramatically slowed the growth of mouse melanoma and colon cancer, even eradicating tumors.
Researchers developed an anti-PD-1 antibody that blocks PD-1/PD-L1 interaction, reinvigorating antivirus immune response and decreasing BLV counts. The new treatment could be effective against various intractable infectious diseases in cows.
Researchers from Florida Atlantic University identified 11 cross-reactive terrestrial-specific antibodies for dolphins, allowing them to assess changes in immune cell populations. The study shows significant differences in the absolute number of cells expressing specific markers within lymphocyte and monocyte fractions.
Researchers have discovered a molecular mechanism behind prion protein's role in neurodegenerative diseases, including Creutzfeldt-Jakob and Alzheimer's. The study found that copper biases the prion protein towards its 'off' state, which reduces toxic signals to nerve cells.
Researchers use a redesigned spider venom peptide to deliver biomacromolecules like antibodies into cells, enabling tracking and interaction with target proteins. The technology improves understanding of protein behavior and could lead to new treatments and drug delivery.
AbeXXa Biologics identifies targets for cancer treatment from thousands of intracellular proteins, potentially resulting in effective immunotherapies for broad patient groups. The company is developing T cell receptor-like antibody-drug complexes to kill tumor cells with low peptide/HLA targets.
Researchers at Brigham and Women's Hospital have developed an antibody that can precisely target regulatory T cells, unleashing the immune system to kill cancer cells. The antibody decreased tumor growth in models of melanoma, glioblastoma, and colorectal carcinoma.
An international team of researchers has identified two receptors on blood vessel cells in the brain that can be blocked to prevent pneumococci from entering. Blocking these receptors with antibodies may lead to a new therapeutic strategy for pneumococcal meningitis.
Researchers at Stanford University School of Medicine have shown that antibodies to PD-1 and PD-L1 can also prompt immune cells called macrophages to engulf and devour cancer cells, expanding the use of this cancer treatment.
Scientists at EPFL developed an antibody-linked biosensor that can track drug concentration in the blood by changing color, enabling patients to monitor their treatment levels at home. The biosensor can be adapted to detect virtually unlimited number of molecules.